Population Pharmacokinetic Modeling of Tremelimumab in Patients with Advanced Solid Tumors and the Impact of Disease Status on Time-varying Clearance.

Michael HwangYen Lin ChiaYanan ZhengCecil Chi-Keung ChenJimmy HeXuyang SongDiansong ZhouSarah B GoldbergLillian L SiuDavid PlanchardSolange PetersHelen MannLee KrugCaroline Even

Published in: British journal of clinical pharmacology (2022)

Tremelimumab exhibited linear pharmacokinetics but consistently opposite trends of time-varying clearance as monotherapy and in combination with durvalumab. Baseline bodyweight and albumin were significant covariates, but conversion from weight-based dosing at 1 mg/kg to flat dosing at 75 mg had no clinically relevant impact.

Keyphrases

body mass index
weight loss
physical activity
combination therapy
open label
randomized controlled trial